Adeno-Associated Virus Gene Therapy for Diabetes and Obesity

This invention is directed to adeno-associated virus (AAV) vector delivery of exendin-4 (Ex-4) to salivary glands as treatment for diabetes and obesity. Ex-4 is a potent and long-acting agonist of the receptor for glucagon-like peptide 1 (GLP-1). Scientists at NIDCR have shown that AAV-mediated delivery of Ex-4 resulted in improved glucose homeostasis and weight profile in two rat models of obesity and type 2 diabetes. Further, AAV-mediated delivery of Ex-4 to rat salivary glands resulted in localized and sustained expression of Ex-4 that was biologically active and well tolerated.

AAV-mediated delivery of Ex-4 is superior to administering GLP-1 analogs in that AAV-Ex-4 expression is more stable and longer acting. Like GLP-1 analogs, Ex-4 expression also potentially provides beneficial effects like reduced hypoglycemia, appetite suppression, and potential weight loss.

Potential Commercial Applications:		Competitive Advantages:
Therapy for diabetes or obesity.		Potential for potent glucose homeostasis therapy with longer duration than current drugs. More convenient than daily or weekly injections.

Development Stage:

• Early-stage
• In vitro data available
• In vivo data available (animal)

Inventors:

John Chiorini (NIDCR)  ➽ more inventions...

Giovanni Di Pasquale (NIDCR)  ➽ more inventions...

Edward Mannucci


Intellectual Property:
US Pat: 10,300,095 issued 2019-05-28
US Pat: 9,511,103 issued 2016-12-06
PCT Application No. PCT/US12/34268 filed on 2012-04-19
US Application No. 14/112,790 filed on 2014-03-20
US Application No. 16/396,262 filed on 2019-04-26

Publications:
Di Pasquale G, et al. PMID 22808093

Collaboration Opportunity:
The NIDCR is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize treatment of diabetes by expression NGF-extendin 4 protein. For collaboration opportunities, please contact David Bradley, Ph.D. at 301-402-9242 or bradleyda@nidcr.nih.gov.


Licensing Contact:
Vladimir Knezevic, M.D.
Email: vlado.knezevic@nih.gov
Phone: 301.443.5560

OTT Reference No: E-142-2011-0
Updated: Nov 2, 2016